Trial reportPsychological medicine2023
Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial.
Trial report in Psychological medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- A systematic review and meta-analysis of transdiagnostic cognitive behavioural therapies for emotional disorders.Nature human behaviour · 2024Pooled it
- Preliminary Findings on the Unified Protocol for Transdiagnostic Treatment: A Pilot Trial on Its Effectiveness on Anxiety and Depressive Symptoms for Turkish Adults.Journal of clinical psychology · 2026Trial
- Cognitive Reappraisal as a Potential Mechanism of Unified Protocol for Emotional Disorders.Behavior therapy · 2025Trial
- Effectiveness of unified protocols for transdiagnostic treatment in improving the symptoms of depression, stress, anxiety, emotion regulation, and cognitive flexibility of students with subclinical symptoms of emotional disorders: A randomized clinical trial.Journal of education and health promotion · 2026Article
- Mapping memory at scale: systems-level insights with translational and transdiagnostic relevance to fear-related disorders.Frontiers in behavioral neuroscience · 2026Review
- Effect of unified transdiagnostic treatment on negative affect, anxiety, and difficulties in emotional regulation in obese children: A randomized controlled trial.Journal of education and health promotion · 2025Article
- Article
- The effectiveness of an unified transdiagnostic intervention based on common mechanisms on the obsessive-compulsive personality pattern.Journal of education and health promotion · 2025Article
- Factors encouraging participation in social activities after hospital discharge in people with severe mental illness who received occupational therapy.Frontiers in psychiatry · 2024Article
- Cultural Adaptation and Implementation of Cognitive-Behavioral Psychosocial Interventions for Anxiety and Depression in Japanese Youth.Clinical child and family psychology review · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of the unified protocol of the transdiagnostic treatment for emotional disorders (UP) has been poorly studied in patients with depressive disorders. This study aimed to examine the efficacy of UP for improving depressive symptoms in patients with depressive and/or anxiety-related disorders.
methodsThis assessor-blinded, randomized, 20-week, parallel-group, superiority study compared the efficacy of the UP with treatment-as-usual (UP-TAU)
resultsIn total, 104 patients participated and were subjected to intention-to-treat analysis [mean age = 37.4, s.d. = 11.5, 63 female (61%), 54 (51.9%) with a principal diagnosis of depressive disorders]. The mean GRID-HAMD scores in the UP-TAU and WL-TAU groups were 16.15 (s.d. = 4.90) and 17.06 (s.d. = 6.46) at baseline and 12.14 (s.d. = 5.47) and 17.34 (s.d. = 5.78) at 21 weeks, with a significant adjusted mean change difference of -3.99 (95% CI -6.10 to -1.87). Patients in the UP-TAU group showed significant superiority in anxiety and clinical global impressions. The improvement in the UP-TAU group was maintained in all outcomes at 43 weeks. No serious adverse events were observed in the UP-TAU group.
conclusionsThe UP is an effective approach for patients with depressive and/or anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.